BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Adams LA, Feldstein A, Lindor KD, Angulo P. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 2004;39:909-14. [PMID: 15057893 DOI: 10.1002/hep.20140] [Cited by in Crossref: 180] [Cited by in F6Publishing: 144] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol Res. 2015;45:363-377. [PMID: 25832328 DOI: 10.1111/hepr.12511] [Cited by in Crossref: 59] [Cited by in F6Publishing: 109] [Article Influence: 8.4] [Reference Citation Analysis]
2 Jung SY, Lee YJ, Lee HJ, Lee YA, Moon JS, Ko JS, Yang SW, Shin CH. Nonalcoholic fatty liver disease in long-term survivors of childhood-onset craniopharyngioma. Ann Pediatr Endocrinol Metab 2017;22:189-96. [PMID: 29025206 DOI: 10.6065/apem.2017.22.3.189] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
3 Pardee PE, Lavine JE, Schwimmer JB. Diagnosis and treatment of pediatric nonalcoholic steatohepatitis and the implications for bariatric surgery. Semin Pediatr Surg 2009;18:144-51. [PMID: 19573756 DOI: 10.1053/j.sempedsurg.2009.04.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
4 Wang WB, She F, Xie LF, Yan WH, Ouyang JZ, Wang BA, Ma HY, Zang L, Mu YM. Evaluation of Basal Serum Adrenocorticotropic Hormone and Cortisol Levels and Their Relationship with Nonalcoholic Fatty Liver Disease in Male Patients with Idiopathic Hypogonadotropic Hypogonadism. Chin Med J (Engl) 2016;129:1147-53. [PMID: 27174321 DOI: 10.4103/0366-6999.181967] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
5 Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, Piemonte F, Marcellini M, Angulo P. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 2008;48:119-28. [PMID: 18537181 DOI: 10.1002/hep.22336] [Cited by in Crossref: 290] [Cited by in F6Publishing: 251] [Article Influence: 20.7] [Reference Citation Analysis]
6 Bellamy C, Burt AD. The Liver in Systemic Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 966-1018. [DOI: 10.1016/b978-0-7020-6697-9.00015-7] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Gilliland T, Dufour S, Shulman GI, Petersen KF, Emre SH. Resolution of non-alcoholic steatohepatitis after growth hormone replacement in a pediatric liver transplant patient with panhypopituitarism. Pediatr Transplant 2016;20:1157-63. [PMID: 27762491 DOI: 10.1111/petr.12819] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
8 Ichikawa T, Nakao K, Hamasaki K, Furukawa R, Tsuruta S, Ueda Y, Taura N, Shibata H, Fujimoto M, Toriyama K. Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatol Int. 2007;1:287-294. [PMID: 19669352 DOI: 10.1007/s12072-007-9007-4] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 4.8] [Reference Citation Analysis]
9 Mann JP, Vreugdenhil A, Socha P, Jańczyk W, Baumann U, Rajwal S, Casswall T, Marcus C, van Mourik I, O'rahilly S, Savage DB, Noble-jamieson G, Lacaille F, Dabbas M, Dubern B, Kelly DA, Nobili V, Anstee QM. European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale. Contemporary Clinical Trials 2018;75:67-71. [DOI: 10.1016/j.cct.2018.11.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
10 Loria P, Lonardo A, Targher G. Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. Clin Sci (Lond). 2008;115:1-12. [PMID: 19016656 DOI: 10.1042/cs20070311] [Cited by in Crossref: 47] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
11 Kawamura Y, Arase Y, Ikeda K, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Inao M, Mochida S, Kumada H. Effects of Alcohol Consumption on Hepatocarcinogenesis in Japanese Patients With Fatty Liver Disease. Clin Gastroenterol Hepatol 2016;14:597-605. [PMID: 26707683 DOI: 10.1016/j.cgh.2015.11.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
12 Cantelli KR, Soares GM, Ribeiro RA, Balbo SL, Lubaczeuski C, Boschero AC, Araújo AC, Bonfleur ML. Duodenal-jejunal bypass normalizes pancreatic islet proliferation rate and function but not hepatic steatosis in hypothalamic obese rats. Braz J Med Biol Res 2017;50:e5858. [PMID: 28380195 DOI: 10.1590/1414-431X20175858] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
13 Van Rooyen DM, Larter CZ, Haigh WG, Yeh MM, Ioannou G, Kuver R, Lee SP, Teoh NC, Farrell GC. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology. 2011;141:1393-1403, 1403.e1-1403.e5. [PMID: 21703998 DOI: 10.1053/j.gastro.2011.06.040] [Cited by in Crossref: 196] [Cited by in F6Publishing: 197] [Article Influence: 17.8] [Reference Citation Analysis]
14 Rafiq N, Younossi ZM. Nonalcoholic fatty liver disease: a practical approach to evaluation and management. Clin Liver Dis. 2009;13:249-266. [PMID: 19442917 DOI: 10.1016/j.cld.2009.02.009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
15 Stiedl P, McMahon R, Blaas L, Stanek V, Svinka J, Grabner B, Zollner G, Kessler SM, Claudel T, Müller M, Mikulits W, Bilban M, Esterbauer H, Eferl R, Haybaeck J, Trauner M, Casanova E. Growth hormone resistance exacerbates cholestasis-induced murine liver fibrosis. Hepatology 2015;61:613-26. [PMID: 25179284 DOI: 10.1002/hep.27408] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
16 Smith SK, Perito ER. Nonalcoholic Liver Disease in Children and Adolescents. Clin Liver Dis 2018;22:723-33. [PMID: 30266159 DOI: 10.1016/j.cld.2018.07.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
17 Birzniece V, Barrett PHR, Ho KKY. Tamoxifen reduces hepatic VLDL production and GH secretion in women: a possible mechanism for steatosis development. European Journal of Endocrinology 2017;177:137-43. [DOI: 10.1530/eje-17-0151] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
18 Hoffmann A, Bootsveld K, Gebhardt U, Daubenbüchel AM, Sterkenburg AS, Müller HL. Nonalcoholic fatty liver disease and fatigue in long-term survivors of childhood-onset craniopharyngioma. Eur J Endocrinol 2015;173:389-97. [PMID: 26088821 DOI: 10.1530/EJE-15-0422] [Cited by in Crossref: 32] [Cited by in F6Publishing: 8] [Article Influence: 4.6] [Reference Citation Analysis]
19 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol 2015;50:364-77. [DOI: 10.1007/s00535-015-1050-7] [Cited by in Crossref: 135] [Cited by in F6Publishing: 66] [Article Influence: 19.3] [Reference Citation Analysis]
20 Mueller KM, Themanns M, Friedbichler K, Kornfeld JW, Esterbauer H, Tuckermann JP, Moriggl R. Hepatic growth hormone and glucocorticoid receptor signaling in body growth, steatosis and metabolic liver cancer development. Mol Cell Endocrinol 2012;361:1-11. [PMID: 22564914 DOI: 10.1016/j.mce.2012.03.026] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
21 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 9] [Article Influence: 0.9] [Reference Citation Analysis]
22 Nyenwe EA, Williamson-Baddorf S, Waters B, Wan JY, Solomon SS. Nonalcoholic Fatty liver disease and metabolic syndrome in hypopituitary patients. Am J Med Sci 2009;338:190-5. [PMID: 19745609 DOI: 10.1097/MAJ.0b013e3181a84bde] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
23 Yuan XX, Zhu HJ, Pan H, Chen S, Liu ZY, Li Y, Wang LJ, Lu L, Yang HB, Gong FY. Clinical characteristics of non-alcoholic fatty liver disease in Chinese adult hypopituitary patients. World J Gastroenterol 2019; 25(14): 1741-1752 [PMID: 31011258 DOI: 10.3748/wjg.v25.i14.1741] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
24 Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009;49:306-17. [PMID: 19065650 DOI: 10.1002/hep.22603] [Cited by in Crossref: 387] [Cited by in F6Publishing: 358] [Article Influence: 29.8] [Reference Citation Analysis]
25 Stanley TL, Fourman LT, Zheng I, McClure CM, Feldpausch MN, Torriani M, Corey KE, Chung RT, Lee H, Kleiner DE, Hadigan CM, Grinspoon SK. Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab 2021;106:e520-33. [PMID: 33125080 DOI: 10.1210/clinem/dgaa792] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
26 Bhanji RA, Watt KD. Fatty allograft and cardiovascular outcomes after liver transplantation. Liver Transpl 2017;23:S76-80. [DOI: 10.1002/lt.24843] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
27 Xue J, Liang S, Ma J, Xiao Y. Effect of growth hormone therapy on liver enzyme and other cardiometabolic risk factors in boys with obesity and nonalcoholic fatty liver disease. BMC Endocr Disord 2022;22:49. [PMID: 35216556 DOI: 10.1186/s12902-022-00967-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
28 Singeap AM, Stanciu C, Huiban L, Muzica CM, Cuciureanu T, Girleanu I, Chiriac S, Zenovia S, Nastasa R, Sfarti C, Cojocariu C, Trifan A. Association between Nonalcoholic Fatty Liver Disease and Endocrinopathies: Clinical Implications. Can J Gastroenterol Hepatol 2021;2021:6678142. [PMID: 33505943 DOI: 10.1155/2021/6678142] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
29 Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology 2020;158:1851-64. [PMID: 32061595 DOI: 10.1053/j.gastro.2020.01.052] [Cited by in Crossref: 120] [Cited by in F6Publishing: 136] [Article Influence: 60.0] [Reference Citation Analysis]
30 Gardner CJ, Irwin AJ, Daousi C, McFarlane IA, Joseph F, Bell JD, Thomas EL, Adams VL, Kemp GJ, Cuthbertson DJ. Hepatic steatosis, GH deficiency and the effects of GH replacement: a Liverpool magnetic resonance spectroscopy study. Eur J Endocrinol. 2012;166:993-1002. [PMID: 22433286 DOI: 10.1530/eje-12-0002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
31 Calderaro J, Zafrani ES. [Non-alcoholic fatty liver disease]. Ann Pathol 2010;30:413-20. [PMID: 21167426 DOI: 10.1016/j.annpat.2010.10.002] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: The present and the future. Digestive and Liver Disease 2009;41:615-25. [DOI: 10.1016/j.dld.2009.01.004] [Cited by in Crossref: 174] [Cited by in F6Publishing: 174] [Article Influence: 13.4] [Reference Citation Analysis]
33 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 1.8] [Reference Citation Analysis]
34 Nagarajan A, Srivastava H, Jablonsky J, Sun LY. Tissue-Specific GHR Knockout Mice: An Updated Review. Front Endocrinol (Lausanne) 2020;11:579909. [PMID: 33162937 DOI: 10.3389/fendo.2020.579909] [Reference Citation Analysis]
35 Auer MK, Stalla GK, Stieg MR. Investigating the role of cortisol and growth hormone in fatty liver development: fatty liver index in patients with pituitary adenomas. Pituitary 2016;19:461-71. [PMID: 27194386 DOI: 10.1007/s11102-016-0726-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
36 Jung D, Seo GH, Kim YM, Choi JH, Yoo HW. Hepatopulmonary syndrome caused by hypothalamic obesity and nonalcoholic fatty liver disease after surgery for craniopharyngioma: a case report. Ann Pediatr Endocrinol Metab 2018;23:51-5. [PMID: 29609450 DOI: 10.6065/apem.2018.23.1.51] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
37 Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta N, Imai N, Kobayashi M, Sezaki H, Matsumoto N. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients. Hepatol Res. 2012;42:264-272. [PMID: 22175908 DOI: 10.1111/j.1872-034x.2011.00915.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
38 Wang T, Yang W, Karakas S, Sarkar S. NASH in Nondiabetic Endocrine Disorders. Metab Syndr Relat Disord 2018;16:315-20. [PMID: 29873585 DOI: 10.1089/met.2018.0044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
39 Xanthakos SA. Nonalcoholic Steatohepatitis in Children. Clin Liver Dis 2022;26:439-60. [PMID: 35868684 DOI: 10.1016/j.cld.2022.05.001] [Reference Citation Analysis]
40 Lindbäck SM, Gabbert C, Johnson BL, Smorodinsky E, Sirlin CB, Garcia N, Pardee PE, Kistler KD, Schwimmer JB. Pediatric Nonalcoholic Fatty Liver Disease: A Comprehensive Review. Advances in Pediatrics 2010;57:85-140. [DOI: 10.1016/j.yapd.2010.08.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
41 Trivin C, Busiah K, Mahlaoui N, Recasens C, Souberbielle JC, Zerah M, Sainte-Rose C, Brauner R. Childhood craniopharyngioma: greater hypothalamic involvement before surgery is associated with higher homeostasis model insulin resistance index. BMC Pediatr 2009;9:24. [PMID: 19341477 DOI: 10.1186/1471-2431-9-24] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
42 Takahashi Y. The Role of Growth Hormone and Insulin-Like Growth Factor-I in the Liver. Int J Mol Sci. 2017;18. [PMID: 28678199 DOI: 10.3390/ijms18071447] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 14.8] [Reference Citation Analysis]
43 Solano-Silva M, Bazán-de Santillana I, Soto-Rodríguez I, Bautista-Piña C, Alexander-Aguilera A. Tissue Changes in the Development of Fatty Liver by Chronic Ingestion of Sucrose Associated with Obesity and Dyslipidemia in Rats. Int J Vitam Nutr Res 2018;88:117-25. [PMID: 31038030 DOI: 10.1024/0300-9831/a000247] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
44 Zhang XY, Yuan K, Fang YL, Wang CL. Growth hormone ameliorates hepatopulmonary syndrome and nonalcoholic steatohepatitis secondary to hypopituitarism in a child: A case report. World J Clin Cases 2022; 10(18): 6211-6217 [DOI: 10.12998/wjcc.v10.i18.6211] [Reference Citation Analysis]
45 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Huang L, Steyn FJ, Tan HY, Xie TY, Veldhuis JD, Ngo ST, Chen C. The decline in pulsatile GH secretion throughout early adulthood in mice is exacerbated by dietary-induced weight gain. Endocrinology 2012;153:4380-8. [PMID: 22802464 DOI: 10.1210/en.2012-1178] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
47 Takahashi Y, Iida K, Takahashi K, Yoshioka S, Fukuoka H, Takeno R, Imanaka M, Nishizawa H, Takahashi M, Seo Y, Hayashi Y, Kondo T, Okimura Y, Kaji H, Kitazawa R, Kitazawa S, Chihara K. Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult growth hormone deficiency. Gastroenterology. 2007;132:938-943. [PMID: 17324404 DOI: 10.1053/j.gastro.2006.12.024] [Cited by in Crossref: 100] [Cited by in F6Publishing: 93] [Article Influence: 6.3] [Reference Citation Analysis]
48 Gonzalez Rozas M, Hernanz Roman L, Gonzalez DG, Pérez-Castrillón JL. Panhypopituitarism due to Absence of the Pituitary Stalk: A Rare Aetiology of Liver Cirrhosis. Case Rep Endocrinol 2016;2016:9071097. [PMID: 27213061 DOI: 10.1155/2016/9071097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
49 Khashab M, Chalasani N. Use of insulin sensitizers in NASH. Endocrinol Metab Clin North Am 2007;36:1067-87; xi. [PMID: 17983937 DOI: 10.1016/j.ecl.2007.07.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
50 Nikolaenko L, Jia Y, Wang C, Diaz-Arjonilla M, Yee JK, French SW, Liu PY, Laurel S, Chong C, Lee K. Testosterone replacement ameliorates nonalcoholic fatty liver disease in castrated male rats. Endocrinology. 2014;155:417-428. [PMID: 24280056 DOI: 10.1210/en.2013-1648] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
51 Koehler E, Watt K, Charlton M. Fatty Liver and Liver Transplantation. Clinics in Liver Disease 2009;13:621-30. [DOI: 10.1016/j.cld.2009.07.010] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
52 Kodama K, Ichihara A, Seki Y, Ikarashi Y, Sagawa T, Kogiso T, Taniai M, Tokushige K. Characteristics of NAFLD Based on Hypopituitarism. Can J Gastroenterol Hepatol 2020;2020:8814435. [PMID: 33102399 DOI: 10.1155/2020/8814435] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
53 Koehler E, Swain J, Sanderson S, Krishnan A, Watt K, Charlton M. Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients. Liver Int. 2012;32:279-286. [PMID: 22098614 DOI: 10.1111/j.1478-3231.2011.02637.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
54 Cabrera D, Cabello-Verrugio C, Solís N, San Martín D, Cofré C, Pizarro M, Arab JP, Abrigo J, Campos F, Irigoyen B, Carrasco-Avino G, Bezares K, Riquelme V, Riquelme A, Arrese M, Barrera F. Somatotropic Axis Dysfunction in Non-Alcoholic Fatty Liver Disease: Beneficial Hepatic and Systemic Effects of Hormone Supplementation. Int J Mol Sci 2018;19:E1339. [PMID: 29724029 DOI: 10.3390/ijms19051339] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
55 Charlton M, Angulo P, Chalasani N, Merriman R, Viker K, Charatcharoenwitthaya P, Sanderson S, Gawrieh S, Krishnan A, Lindor K. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology 2008;47:484-92. [PMID: 18220286 DOI: 10.1002/hep.22063] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 5.2] [Reference Citation Analysis]
56 Cortez-pinto H, Ermelinda Camilo M. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Practice & Research Clinical Gastroenterology 2004;18:1089-104. [DOI: 10.1016/j.bpg.2004.06.021] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 3.1] [Reference Citation Analysis]
57 Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl). 2009;87:679-695. [PMID: 19352614 DOI: 10.1007/s00109-009-0464-1] [Cited by in Crossref: 188] [Cited by in F6Publishing: 174] [Article Influence: 14.5] [Reference Citation Analysis]
58 Ozcelik F, Yuksel C, Arslan E, Genc S, Omer B, Serdar MA. Relationship between visceral adipose tissue and adiponectin, inflammatory markers and thyroid hormones in obese males with hepatosteatosis and insulin resistance. Arch Med Res. 2013;44:273-280. [PMID: 23602473 DOI: 10.1016/j.arcmed.2013.04.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
59 Sarkar M, Wellons M, Cedars MI, VanWagner L, Gunderson EP, Ajmera V, Torchen L, Siscovick D, Carr JJ, Terry JG, Rinella M, Lewis CE, Terrault N. Testosterone Levels in Pre-Menopausal Women are Associated With Nonalcoholic Fatty Liver Disease in Midlife. Am J Gastroenterol 2017;112:755-62. [PMID: 28291240 DOI: 10.1038/ajg.2017.44] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
60 Liebe R, Esposito I, Bock HH, Vom Dahl S, Stindt J, Baumann U, Luedde T, Keitel V. Diagnosis and management of secondary causes of steatohepatitis. J Hepatol 2021;74:1455-71. [PMID: 33577920 DOI: 10.1016/j.jhep.2021.01.045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
61 Doycheva I, Erickson D, Watt KD. Growth hormone deficiency and NAFLD: An overlooked and underrecognized link. Hepatol Commun 2022. [PMID: 35765700 DOI: 10.1002/hep4.1953] [Reference Citation Analysis]
62 Pariente A. [Diagnosis and management of non alcoholic fatty liver disease]. Gastroenterol Clin Biol 2009;33:413-24. [PMID: 19375255 DOI: 10.1016/j.gcb.2009.02.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
63 Prieto-Hontoria PL, Pérez-Matute P, Fernández-Galilea M, Bustos M, Martínez JA, Moreno-Aliaga MJ. Role of obesity-associated dysfunctional adipose tissue in cancer: a molecular nutrition approach. Biochim Biophys Acta 2011;1807:664-78. [PMID: 21111705 DOI: 10.1016/j.bbabio.2010.11.004] [Cited by in Crossref: 92] [Cited by in F6Publishing: 89] [Article Influence: 7.7] [Reference Citation Analysis]
64 Marino L, Jornayvaz FR. Endocrine causes of nonalcoholic fatty liver disease. World J Gastroenterol 2015; 21(39): 11053-11076 [PMID: 26494962 DOI: 10.3748/wjg.v21.i39.11053] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 39] [Article Influence: 6.6] [Reference Citation Analysis]
65 Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33:525-540. [PMID: 21198708 DOI: 10.1111/j.1365-2036.2010.04556.x] [Cited by in Crossref: 209] [Cited by in F6Publishing: 187] [Article Influence: 17.4] [Reference Citation Analysis]
66 Nishizawa H, Iguchi G, Murawaki A, Fukuoka H, Hayashi Y, Kaji H, Yamamoto M, Suda K, Takahashi M, Seo Y, Yano Y, Kitazawa R, Kitazawa S, Koga M, Okimura Y, Chihara K, Takahashi Y. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy. European Journal of Endocrinology 2012;167:67-74. [DOI: 10.1530/eje-12-0252] [Cited by in Crossref: 74] [Cited by in F6Publishing: 27] [Article Influence: 7.4] [Reference Citation Analysis]
67 Jafarian A, Ebrahimi A, Azmoudeh Ardalan F, Dashti H, Rahimi M, Salehi M, Nasiri Toosi M. NAFLD Prevalence in a Young Cadaveric Organ Donor Population. Hepat Mon 2014;14:e21574. [PMID: 25419218 DOI: 10.5812/hepatmon.21574] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
68 Jia Y, Yee JK, Wang C, Nikolaenko L, Diaz-Arjonilla M, Cohen JN, French SW, Liu PY, Lue Y, Lee WP, Swerdloff RS. Testosterone protects high-fat/low-carbohydrate diet-induced nonalcoholic fatty liver disease in castrated male rats mainly via modulating endoplasmic reticulum stress. Am J Physiol Endocrinol Metab 2018;314:E366-76. [PMID: 28928235 DOI: 10.1152/ajpendo.00124.2017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
69 Charlton M. Evolving aspects of liver transplantation for nonalcoholic steatohepatitis. Curr Opin Organ Transplant. 2013;18:251-258. [PMID: 23652610 DOI: 10.1097/mot.0b013e3283615d30] [Cited by in Crossref: 37] [Cited by in F6Publishing: 15] [Article Influence: 4.1] [Reference Citation Analysis]
70 Diniz RD, Souza RM, Salvatori R, Franca A, Gomes-Santos E, Ferrão TO, Oliveira CR, Santana JA, Pereira FA, Barbosa RA, Souza AH, Pereira RM, Oliveira-Santos AA, Silva AM, Santana-Júnior FJ, Valença EH, Campos VC, Aguiar-Oliveira MH. Liver status in congenital, untreated, isolated GH deficiency. Endocr Connect 2014;3:132-7. [PMID: 25117570 DOI: 10.1530/EC-14-0078] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
71 Yu EL, Schwimmer JB. Epidemiology of Pediatric Nonalcoholic Fatty Liver Disease. Clin Liver Dis (Hoboken) 2021;17:196-9. [PMID: 33868665 DOI: 10.1002/cld.1027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
72 Mueller KM, Kornfeld JW, Friedbichler K, Blaas L, Egger G, Esterbauer H, Hasselblatt P, Schlederer M, Haindl S, Wagner KU, Engblom D, Haemmerle G, Kratky D, Sexl V, Kenner L, Kozlov AV, Terracciano L, Zechner R, Schuetz G, Casanova E, Pospisilik JA, Heim MH, Moriggl R. Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology 2011;54:1398-409. [PMID: 21725989 DOI: 10.1002/hep.24509] [Cited by in Crossref: 78] [Cited by in F6Publishing: 71] [Article Influence: 7.1] [Reference Citation Analysis]
73 Roberts EA. Non-alcoholic steatohepatitis in children. Clin Liver Dis. 2007;11:155-172, x. [PMID: 17544977 DOI: 10.1016/j.cld.2007.02.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
74 Guarnotta V, Mineo MI, Radellini S, Pizzolanti G, Giordano C. Dual-release hydrocortisone improves hepatic steatosis in patients with secondary adrenal insufficiency: a real-life study. Ther Adv Endocrinol Metab 2019;10:2042018819871169. [PMID: 31489172 DOI: 10.1177/2042018819871169] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
75 Pacifico L, Poggiogalle E, Cantisani V, Menichini G, Ricci P, Ferraro F, Chiesa C. Pediatric nonalcoholic fatty liver disease: A clinical and laboratory challenge. World J Hepatol 2010; 2(7): 275-288 [PMID: 21161009 DOI: 10.4254/wjh.v2.i7.275] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
76 Henry RK. When They're Done Growing, Don't Forget They May Still Need Growth Hormone. Metab Syndr Relat Disord 2021;19:257-63. [PMID: 33596132 DOI: 10.1089/met.2020.0130] [Reference Citation Analysis]
77 Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2014;59:1174-97. [PMID: 24002776 DOI: 10.1002/hep.26717] [Cited by in Crossref: 351] [Cited by in F6Publishing: 307] [Article Influence: 43.9] [Reference Citation Analysis]
78 Barclay JL, Nelson CN, Ishikawa M, Murray LA, Kerr LM, McPhee TR, Powell EE, Waters MJ. GH-dependent STAT5 signaling plays an important role in hepatic lipid metabolism. Endocrinology. 2011;152:181-192. [PMID: 21084450 DOI: 10.1210/en.2010-0537] [Cited by in Crossref: 106] [Cited by in F6Publishing: 100] [Article Influence: 8.8] [Reference Citation Analysis]
79 Fukunaga K, Imachi H, Lyu J, Dong T, Sato S, Ibata T, Kobayashi T, Yoshimoto T, Yonezaki K, Matsunaga T, Murao K. IGF1 suppresses cholesterol accumulation in the liver of growth hormone-deficient mice via the activation of ABCA1. American Journal of Physiology-Endocrinology and Metabolism 2018;315:E1232-41. [DOI: 10.1152/ajpendo.00134.2018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
80 Burra P. Liver abnormalities and endocrine diseases. Best Pract Res Clin Gastroenterol. 2013;27:553-563. [PMID: 24090942 DOI: 10.1016/j.bpg.2013.06.014] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
81 Xanthakos SA, Crimmins NA, Chernausek SD. Abnormalities in the growth hormone axis and risk of nonalcoholic steatohepatitis: active player or innocent bystander? J Pediatr 2014;165:12-4. [PMID: 24793205 DOI: 10.1016/j.jpeds.2014.03.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
82 Goltz D, Schötta K, Zhou H, Fischer H. Nichtalkoholische Steatohepatitis mit Zirrhose bei jungen Erwachsenen mit hypothalamisch-hypophysärer Dysfunktion. Pathologe 2013;34:318-22. [DOI: 10.1007/s00292-012-1735-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
83 Li X, Guan Y, Li Y, Wu D, Liu L, Deng Q, Li X, Wang Z, Liu G. Effects of insulin-like growth factor-1 on the assembly and secretion of very low-density lipoproteins in cow hepatocytes in vitro. General and Comparative Endocrinology 2016;226:82-7. [DOI: 10.1016/j.ygcen.2015.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
84 Lonardo A, Mantovani A, Lugari S, Targher G. NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management. Int J Mol Sci. 2019;20. [PMID: 31212642 DOI: 10.3390/ijms20112841] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 14.7] [Reference Citation Analysis]
85 Runde J, Azzam RK. Hepatobiliary Manifestations in Systemic Disease. Pediatr Ann 2018;47:e458-64. [PMID: 30423189 DOI: 10.3928/19382359-20181023-01] [Reference Citation Analysis]
86 Villanueva-Ortega E, Méndez-García LA, Garibay-Nieto GN, Laresgoiti-Servitje E, Medina-Bravo P, Olivos-García A, Muñoz-Ortega MH, Ventura-Juárez J, Escobedo G. Growth hormone ameliorates high glucose-induced steatosis on in vitro cultured human HepG2 hepatocytes by inhibiting de novo lipogenesis via ChREBP and FAS suppression. Growth Horm IGF Res 2020;53-54:101332. [PMID: 32698101 DOI: 10.1016/j.ghir.2020.101332] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
87 Larrain S, Rinella ME. A myriad of pathways to NASH. Clin Liver Dis. 2012;16:525-548. [PMID: 22824479 DOI: 10.1016/j.cld.2012.05.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
88 Jonas MM, Krawczuk LE, Kim HB, Lillehei C, Perez-Atayde A. Rapid recurrence of nonalcoholic fatty liver disease after transplantation in a child with hypopituitarism and hepatopulmonary syndrome. Liver Transpl. 2005;11:108-110. [PMID: 15690545 DOI: 10.1002/lt.20332] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
89 Nishizawa H, Takahashi M, Fukuoka H, Iguchi G, Kitazawa R, Takahashi Y. GH-independent IGF-I action is essential to prevent the development of nonalcoholic steatohepatitis in a GH-deficient rat model. Biochem Biophys Res Commun. 2012;423:295-300. [PMID: 22659415 DOI: 10.1016/j.bbrc.2012.05.115] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
90 Crespo M, Lappe S, Feldstein AE, Alkhouri N. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. Metabolism 2016;65:1161-71. [DOI: 10.1016/j.metabol.2016.01.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 7.7] [Reference Citation Analysis]
91 Arase Y, Kawamura Y, Seko Y, Kobayashi M, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Sezaki H, Saito S. Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease. Hepatol Res. 2013;43:1163-1168. [PMID: 23489256 DOI: 10.1111/hepr.12077] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
92 Hunter AK, Lin HC. Review of Clinical Guidelines in the Diagnosis of Pediatric Nonalcoholic Fatty Liver Disease. Clin Liver Dis (Hoboken) 2021;18:40-4. [PMID: 34484704 DOI: 10.1002/cld.1094] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
93 van Aken MO, Lamberts SWJ. Diagnosis and Treatment of Hypopituitarism: An Update. Pituitary 2005;8:183-91. [DOI: 10.1007/s11102-006-6039-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
94 Xu L, Xu C, Yu C, Miao M, Zhang X, Zhu Z, Ding X, Li Y. Association between serum growth hormone levels and nonalcoholic fatty liver disease: a cross-sectional study. PLoS One. 2012;7:e44136. [PMID: 22952901 DOI: 10.1371/journal.pone.0044136] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
95 Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009;58:1538-44. [PMID: 19625277 DOI: 10.1136/gut.2008.171280] [Cited by in Crossref: 449] [Cited by in F6Publishing: 415] [Article Influence: 34.5] [Reference Citation Analysis]
96 Mager DR, Roberts EA. Nonalcoholic Fatty Liver Disease in Children. Clinics in Liver Disease 2006;10:109-31. [DOI: 10.1016/j.cld.2005.10.007] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
97 Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43:S99-S112. [PMID: 16447287 DOI: 10.1002/hep.20973] [Cited by in Crossref: 1697] [Cited by in F6Publishing: 1580] [Article Influence: 106.1] [Reference Citation Analysis]
98 Loria P, Lonardo A, Bellentani S, Day CP, Marchesini G, Carulli N. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis. 2007;17:684-698. [PMID: 17560098 DOI: 10.1016/j.numecd.2007.01.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 3.7] [Reference Citation Analysis]
99 Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-384. [PMID: 20494470 DOI: 10.1016/j.jhep.2010.04.008] [Cited by in Crossref: 637] [Cited by in F6Publishing: 605] [Article Influence: 53.1] [Reference Citation Analysis]
100 Tateno C, Kataoka M, Utoh R, Tachibana A, Itamoto T, Asahara T, Miya F, Tsunoda T, Yoshizato K. Growth Hormone-Dependent Pathogenesis of Human Hepatic Steatosis in a Novel Mouse Model Bearing a Human Hepatocyte-Repopulated Liver. Endocrinology 2011;152:1479-91. [DOI: 10.1210/en.2010-0953] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
101 Alabsawy E, Serry Y, Kotha S, Berry P, Tritto G. Hepatopulmonary syndrome as the first and only manifestation of cirrhosis in a patient with hypopituitarism. BMJ Case Rep 2021;14:e244805. [PMID: 34544714 DOI: 10.1136/bcr-2021-244805] [Reference Citation Analysis]
102 Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol. 2016;13:196-205. [PMID: 26907882 DOI: 10.1038/nrgastro.2016.3] [Cited by in Crossref: 186] [Cited by in F6Publishing: 171] [Article Influence: 31.0] [Reference Citation Analysis]
103 Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ohmoto Y, Amakawa K, Tsuji H, Kumada H. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol. 2012;107:253-261. [PMID: 22008893 DOI: 10.1038/ajg.2011.327] [Cited by in Crossref: 148] [Cited by in F6Publishing: 154] [Article Influence: 13.5] [Reference Citation Analysis]
104 Cianfarani S, Inzaghi E, Alisi A, Germani D, Puglianiello A, Nobili V. Insulin-like growth factor-I and -II levels are associated with the progression of nonalcoholic fatty liver disease in obese children. J Pediatr 2014;165:92-8. [PMID: 24607243 DOI: 10.1016/j.jpeds.2014.01.052] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
105 Wu ZY, Li YL, Chang B. Pituitary stalk interruption syndrome and liver changes: From clinical features to mechanisms. World J Gastroenterol 2020; 26(44): 6909-6922 [PMID: 33311939 DOI: 10.3748/wjg.v26.i44.6909] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Ji W, Nie M, Mao JF, Zhang HB, Wang X, Wu XY. Growth hormone cocktail improves hepatopulmonary syndrome secondary to hypopituitarism: A case report. World J Clin Cases 2021; 9(18): 4852-4858 [PMID: 34222458 DOI: 10.12998/wjcc.v9.i18.4852] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
107 Singal AK, Charlton M. Transplantation for Nonalcoholic Steatohepatitis. Transplantation of the Liver. Elsevier; 2015. pp. 250-5. [DOI: 10.1016/b978-1-4557-0268-8.00022-1] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
108 Minemura M, Tajiri K, Shimizu Y. Systemic abnormalities in liver disease. World J Gastroenterol 2009;15:2960-74. [PMID: 19554648 DOI: 10.3748/wjg.15.2960] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
109 Loria P, Carulli L, Bertolotti M, Lonardo A. Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol. 2009;6:236-247. [PMID: 19347015 DOI: 10.1038/nrgastro.2009.33] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 7.2] [Reference Citation Analysis]
110 Kotler DP, He Q, Engelson ES, Albu JB, Glesby MJ. The effect of recombinant human growth hormone with or without rosiglitazone on hepatic fat content in HIV-1-infected individuals: a randomized clinical trial. Antivir Ther 2016;21:107-16. [PMID: 25536669 DOI: 10.3851/IMP2927] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
111 Kaltenecker D, Themanns M, Mueller KM, Spirk K, Suske T, Merkel O, Kenner L, Luís A, Kozlov A, Haybaeck J, Müller M, Han X, Moriggl R. Hepatic growth hormone - JAK2 - STAT5 signalling: Metabolic function, non-alcoholic fatty liver disease and hepatocellular carcinoma progression. Cytokine 2019;124:154569. [PMID: 30389231 DOI: 10.1016/j.cyto.2018.10.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
112 Nagoya T, Kamimura K, Inoue R, Ko M, Owaki T, Niwa Y, Sakai N, Setsu T, Sakamaki A, Yokoo T, Kamimura H, Nakamura Y, Ueno M, Terai S. Ghrelin-insulin-like growth factor-1 axis is activated via autonomic neural circuits in the non-alcoholic fatty liver disease. Neurogastroenterol Motil 2020;32:e13799. [PMID: 31984635 DOI: 10.1111/nmo.13799] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
113 Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, Mouzaki M, Sathya P, Schwimmer JB, Sundaram SS, Xanthakos SA. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017;64:319-34. [PMID: 28107283 DOI: 10.1097/MPG.0000000000001482] [Cited by in Crossref: 306] [Cited by in F6Publishing: 133] [Article Influence: 76.5] [Reference Citation Analysis]
114 Vilarinho S, Ajmera V, Zheng M, Loomba R. Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD. Hepatology 2021;74:2241-50. [PMID: 34233030 DOI: 10.1002/hep.32047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
115 Wilson CG, Tran JL, Erion DM, Vera NB, Febbraio M, Weiss EJ. Hepatocyte-Specific Disruption of CD36 Attenuates Fatty Liver and Improves Insulin Sensitivity in HFD-Fed Mice. Endocrinology. 2016;157:570-585. [PMID: 26650570 DOI: 10.1210/en.2015-1866] [Cited by in Crossref: 169] [Cited by in F6Publishing: 167] [Article Influence: 24.1] [Reference Citation Analysis]
116 Nobili V, Alkhouri N, Alisi A, Ottino S, Lopez R, Manco M, Feldstein AE. Retinol-Binding Protein 4: A Promising Circulating Marker of Liver Damage in Pediatric Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology 2009;7:575-9. [DOI: 10.1016/j.cgh.2008.12.031] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 4.1] [Reference Citation Analysis]
117 Suri A, Song E, van Nispen J, Voigt M, Armstrong A, Murali V, Jain A. Advances in the Epidemiology, Diagnosis, and Management of Pediatric Fatty Liver Disease. Clin Ther 2021;43:438-54. [PMID: 33597074 DOI: 10.1016/j.clinthera.2021.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Chavez-Tapia NC, Sanchez-Avila F, Vasquez-Fernandez F, Torres-Machorro A, Tellez-Avila FI, Uribe M. Non-alcoholic fatty-liver disease in pediatric populations. J Pediatr Endocrinol Metab 2007;20:1059-73. [PMID: 18051925 DOI: 10.1515/jpem.2007.20.10.1059] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
119 Ranucci G, Spagnuolo MI, Iorio R. Obese children with fatty liver: Between reality and disease mongering. World J Gastroenterol 2017; 23(47): 8277-8282 [PMID: 29307987 DOI: 10.3748/wjg.v23.i47.8277] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
120 Maheshwari A, Thuluvath PJ. Endocrine diseases and the liver. Clin Liver Dis 2011;15:55-67. [PMID: 21111993 DOI: 10.1016/j.cld.2010.09.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
121 Yuk T, Kim Y, Yang J, Sung J, Jeong HS, Lee J. Nobiletin Inhibits Hepatic Lipogenesis via Activation of AMP-Activated Protein Kinase. Evid Based Complement Alternat Med 2018;2018:7420265. [PMID: 29552085 DOI: 10.1155/2018/7420265] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
122 Roberts EA. Pediatric nonalcoholic fatty liver disease (NAFLD): A “growing” problem? Journal of Hepatology 2007;46:1133-42. [DOI: 10.1016/j.jhep.2007.03.003] [Cited by in Crossref: 123] [Cited by in F6Publishing: 102] [Article Influence: 8.2] [Reference Citation Analysis]
123 Sahakitrungruang T, Klomchan T, Supornsilchai V, Wacharasindhu S. Obesity, metabolic syndrome, and insulin dynamics in children after craniopharyngioma surgery. Eur J Pediatr 2011;170:763-9. [DOI: 10.1007/s00431-010-1347-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
124 Diehl AM, Choi SS. The Liver in Type 2 Diabetes Mellitus. In: Feinglos MN, Bethel MA, editors. Type 2 Diabetes Mellitus. Totowa: Humana Press; 2008. pp. 351-64. [DOI: 10.1007/978-1-60327-043-4_21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
125 Henry RK. Growth Hormone Deficiency and Nonalcoholic Fatty Liver Disease with Insights from Humans and Animals: Pediatric Implications. Metabolic Syndrome and Related Disorders 2018;16:507-13. [DOI: 10.1089/met.2018.0056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
126 Mărginean CO, Meliț LE, Săsăran MO. Metabolic Associated Fatty Liver Disease in Children-From Atomistic to Holistic. Biomedicines 2021;9:1866. [PMID: 34944682 DOI: 10.3390/biomedicines9121866] [Reference Citation Analysis]
127 Justino H, Sanders K, Mclin VA. Rapid Progression From Hepatopulmonary Syndrome to Portopulmonary Hypertension in an Adolescent Female With Hypopituitarism. Journal of Pediatric Gastroenterology & Nutrition 2010;50:334-6. [DOI: 10.1097/mpg.0b013e3181a1c496] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
128 Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol. 2007;17:863-869. [PMID: 17728149 DOI: 10.1016/j.annepidem.2007.05.013] [Cited by in Crossref: 197] [Cited by in F6Publishing: 191] [Article Influence: 13.1] [Reference Citation Analysis]
129 Lonardo A, Lombardini S, Ricchi M, Scaglioni F, Loria P. Review article: hepatic steatosis and insulin resistance. Aliment Pharmacol Ther 2005;22:64-70. [DOI: 10.1111/j.1365-2036.2005.02600.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 3.6] [Reference Citation Analysis]
130 Loria P, Carulli L, Bertolotti M, Lonardo A. Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol. 2009;6:236-247. [PMID: 19347015 DOI: 10.1038/nrgatro.2009.33] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
131 Arase Y, Suzuki F, Ikeda K, Kumada H, Tsuji H, Kobayashi T. Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease. J Gastroenterol. 2009;44:1064-1070. [PMID: 19533014 DOI: 10.1007/s00535-009-0091-1] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
132 Soares GM, Cantelli KR, Balbo SL, Ribeiro RA, Alegre-Maller ACP, Barbosa-Sampaio HC, Boschero AC, Araújo ACF, Bonfleur ML. Liver steatosis in hypothalamic obese rats improves after duodeno-jejunal bypass by reduction in de novo lipogenesis pathway. Life Sci 2017;188:68-75. [PMID: 28866102 DOI: 10.1016/j.lfs.2017.08.035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
133 Al-Massadi O, Parini P, Fernø J, Luquet S, Quiñones M. Metabolic actions of the growth hormone-insulin growth factor-1 axis and its interaction with the central nervous system. Rev Endocr Metab Disord 2022. [PMID: 35687272 DOI: 10.1007/s11154-022-09732-x] [Reference Citation Analysis]
134 Zhang S, Lu C, Das AK, Pasupulati AK, Menon RK. Abrogation of GH action in Kupffer cells results in increased hepatic CD36 expression and exaggerated nonalcoholic fatty liver disease. Growth Horm IGF Res 2018;42-43:74-9. [PMID: 30321786 DOI: 10.1016/j.ghir.2018.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
135 Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005;22:1129-33. [DOI: 10.1111/j.1464-5491.2005.01748.x] [Cited by in Crossref: 200] [Cited by in F6Publishing: 196] [Article Influence: 11.8] [Reference Citation Analysis]
136 Alfire ME, Treem WR. Nonalcoholic fatty liver disease. Pediatr Ann 2006;35:290-4, 297-9. [PMID: 16637558 DOI: 10.3928/0090-4481-20060401-14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
137 Vos MB. NAFLD in the transition from adolescence to young adulthood: NAFLD From Adolescence to Young Adulthood. Clinical Liver Disease 2014;4:93-5. [DOI: 10.1002/cld.422] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
138 Kang SJ, Kwon A, Jung MK, Chae HW, Kim S, Koh H, Shin HJ, Kim HS. High Prevalence of Nonalcoholic Fatty Liver Disease Among Adolescents and Young Adults With Hypopituitarism due to Growth Hormone Deficiency. Endocr Pract 2021:S1530-891X(21)01081-8. [PMID: 34126247 DOI: 10.1016/j.eprac.2021.06.003] [Reference Citation Analysis]
139 Cotter TG, Charlton M. Nonalcoholic Steatohepatitis After Liver Transplantation. Liver Transpl 2019;26:141-59. [DOI: 10.1002/lt.25657] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
140 Lonardo A, Carani C, Carulli N, Loria P. ‘Endocrine NAFLD’ a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol. 2006;44:1196-1207. [PMID: 16618516 DOI: 10.1016/j.jhep.2006.03.005] [Cited by in Crossref: 88] [Cited by in F6Publishing: 91] [Article Influence: 5.5] [Reference Citation Analysis]
141 Lee YY, Wong TT, Fang YT, Chang KP, Chen YW, Niu DM. Comparison of hypothalamopituitary axis dysfunction of intrasellar and third ventricular craniopharyngiomas in children. Brain Dev 2008;30:189-94. [PMID: 17870266 DOI: 10.1016/j.braindev.2007.07.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
142 Shneider BL, González-Peralta R, Roberts EA. Controversies in the management of pediatric liver disease: Hepatitis B, C and NAFLD: Summary of a single topic conference. Hepatology 2006;44:1344-54. [PMID: 17058223 DOI: 10.1002/hep.21373] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
143 Han Y, Lin M, Wang X, Guo K, Wang S, Sun M, Wang J, Han X, Fu T, Hu Y, Fu J. Basis of aggravated hepatic lipid metabolism by chronic stress in high-fat diet-fed rat. Endocrine 2015;48:483-92. [PMID: 24895043 DOI: 10.1007/s12020-014-0307-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
144 Jang HS, Kim K, Lee MR, Kim SH, Choi JH, Park MJ. Treatment of growth hormone attenuates hepatic steatosis in hyperlipidemic mice via downregulation of hepatic CD36 expression. Anim Cells Syst (Seoul) 2020;24:151-9. [PMID: 33209195 DOI: 10.1080/19768354.2020.1778080] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Torii N, Ichihara A, Mizuguchi Y, Seki Y, Hashimoto E, Tokushige K. Hormone-replacement Therapy for Hepatopulmonary Syndrome and NASH Associated with Hypopituitarism. Intern Med. 2018;57:1741-1745. [PMID: 29910217 DOI: 10.2169/internalmedicine.0027-17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
146 Wieckowska A, Feldstein AE. Nonalcoholic fatty liver disease in the pediatric population: a review. Curr Opin Pediatr. 2005;17:636-641. [PMID: 16160540 DOI: 10.1097/01.mop.0000172816.79637.c5] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 5.3] [Reference Citation Analysis]
147 Laron Z, Ginsberg S, Webb M. Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion - preliminary report. Growth Horm IGF Res. 2008;18:434-438. [PMID: 18462969 DOI: 10.1016/j.ghir.2008.03.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
148 Dowman JK, Armstrong MJ, Tomlinson JW, Newsome PN. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes, Obesity and Metabolism 2011;13:692-702. [DOI: 10.1111/j.1463-1326.2011.01403.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 7.3] [Reference Citation Analysis]
149 Guichelaar MM, Charlton MR. Decreased muscle mass in nonalcoholic fatty liver disease: new evidence of a link between growth hormone and fatty liver disease? Hepatology 2014;59:1668-70. [PMID: 24691865 DOI: 10.1002/hep.27058] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
150 Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci. 2005;50:171-180. [PMID: 15712657 DOI: 10.1007/s10620-005-1267-z] [Cited by in Crossref: 169] [Cited by in F6Publishing: 163] [Article Influence: 9.9] [Reference Citation Analysis]
151 Sato T, Katabami T, Furukawa K, Narimatsu H, Hashimoto T, Nakajima Y, Ohta A, Sasaoka T, Tanaka Y. Intracellular lipid content of liver and skeletal muscle in patients with adult growth hormone deficiency without diabetes mellitus. Obesity Research & Clinical Practice 2012;6:e321-9. [DOI: 10.1016/j.orcp.2011.09.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
152 Pan CS, Weiss JJ, Fourman LT, Buckless C, Branch KL, Lee H, Torriani M, Misra M, Stanley TL. Effect of recombinant human growth hormone on liver fat content in young adults with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2021;94:183-92. [PMID: 33037656 DOI: 10.1111/cen.14344] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
153 Deng XL, Ma R, Zhu HX, Zhu J. Short article: A randomized-controlled study of sitagliptin for treating diabetes mellitus complicated by nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2017;29:297-301. [PMID: 27832040 DOI: 10.1097/MEG.0000000000000780] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]